Blue Trust Inc. Makes New Investment in DiaMedica Therapeutics Inc. (NASDAQ:DMAC)

Blue Trust Inc. acquired a new stake in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 44,247 shares of the company’s stock, valued at approximately $185,000. Blue Trust Inc. owned 0.10% of DiaMedica Therapeutics at the end of the most recent reporting period.

Separately, Magnolia Capital Advisors LLC bought a new stake in DiaMedica Therapeutics in the 2nd quarter valued at about $87,000. Hedge funds and other institutional investors own 10.12% of the company’s stock.

DiaMedica Therapeutics Stock Performance

Shares of DMAC opened at $4.39 on Friday. The stock’s 50-day simple moving average is $4.18 and its 200 day simple moving average is $3.39. The stock has a market capitalization of $187.64 million, a price-to-earnings ratio of -7.84 and a beta of 1.48. DiaMedica Therapeutics Inc. has a 52-week low of $2.05 and a 52-week high of $4.95.

DiaMedica Therapeutics (NASDAQ:DMAC) last issued its quarterly earnings results on Wednesday, August 7th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.03. During the same period in the prior year, the company posted ($0.16) EPS. On average, research analysts forecast that DiaMedica Therapeutics Inc. will post -0.58 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on DMAC shares. Oppenheimer restated an “outperform” rating and issued a $6.00 target price on shares of DiaMedica Therapeutics in a report on Friday, August 16th. HC Wainwright began coverage on DiaMedica Therapeutics in a report on Monday, October 7th. They issued a “buy” rating and a $7.00 target price on the stock.

DiaMedica Therapeutics Profile

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.